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peginterferon-alfa-2a (40 KD) to be a cost-effective therapy for
the private health care system in Brazil.
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OBJECTIVES: Studies have shown similar clinical cure rates and
shorter length of stay (LOS) for linezolid compared to vancomy-
cin in patients with complicated skin and soft tissue infections
(cSSTI) due to suspected or proven methicillin-resistant Staphy-
lococcus aureus (MRSA). This study examined the clinical and
economic consequences of using linezolid vs. vancomycin from
the French health system perspective. METHODS: A decision-
analytic model followed an average patient from initiation of
empiric treatment until successful 1st-line treatment, death, or
2nd-line treatment failure. Efﬁcacy data were derived from pub-
lished clinical trials. Resource utilization patterns were collected
through structured interviews with 4 French physicians experi-
enced in treating cSSTI. Costs from ofﬁcial price and tariff lists
were applied to antibiotics therapy, hospitalisation (by ward
type), isolation, tests, adverse events, and post-discharge.
Patients could be discharged to oral linezolid. The base case used
therapy duration and LOS from the expert panel. Outcomes
included total cost per patient, and cost per cure. RESULTS:
Average total cost per episode was €7784 for linezolid vs. €8514
for vancomycin (cost savings of €730 mostly due to reduction in
hospitalization costs from earlier discharge). Mean LOS after
two lines of treatment was 10.7 days for linezolid vs. 13.3 days
for vancomycin. An additional 0.5% of patients treated with
linezolid (98.5%) vs. vancomycin (98.0%) were cured. Slight
increase in effectiveness and reduced cost made linezolid the
dominant treatment strategy. One-way sensitivity analysis on
selected parameters (50% variation above or below baseline),
and a conservative scenario with simultaneous changes in key
parameters, did not change the overall conclusions (linezolid
remained cost-saving). CONCLUSION: This model showed that
linezolid could be cost saving when treating patients with cSSTI
due to suspected MRSA, while overall clinical cure was similar.
Linezolid could therefore be considered an efﬁcient strategy for
treating cSSTI in France.
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OBJECTIVES: Linezolid has demonstrated improved survival
and clinical cure rates in hospitalised patients with nosocomial
pneumonia (NP) caused by known or suspected methicillin-
resistant Staphylococcus aureus (MRSA). This study assessed the
cost-effectiveness of linezolid vs. vancomycin from the perspec-
tive of the French health system. METHODS: A decision-
analytic model followed an average patient from initiation of
empiric treatment until successful 1st-line treatment, death, or
2nd-line treatment failure. Efﬁcacy data were derived from pub-
lished clinical trials. Five French physicians experienced in treat-
ing NP provided resource utilization data through structured
interviews. Costs from ofﬁcial price and tariff lists were applied
to antibiotic therapy, hospitalisation (by ward type), isolation,
tests, and adverse events. The model applied similar length of
successful 1st-line treatment for linezolid and vancomycin. The
model base case conservatively assumed that length of stay was
equal to therapy duration. Outcomes included total cost per
patient, cost per cure, cost per death avoided, and cost per life
year gained. RESULTS: An additional 7.6% of patients treated
with linezolid (70.9%) vs. vancomycin (63.2%) were cured.
Average total cost per episode was €16,732 for linezolid vs.
€15,375 for vancomycin, Modelled survival was 80.4% (lin-
ezolid) vs. 69.7% (vancomycin), resulting in an average 2.0
life-years gained per linezolid patient in a 65-year-old cohort
(14.9 vs. 13.0 years). Costs per life-year gained (excluding future
costs) and death avoided were €685 and €12,727, respectively.
One-way sensitivity analysis on selected parameters (50%
variation above or below baseline) did not change the overall
conclusions. CONCLUSION: Improved clinical outcomes, but
increased cost per episode were calculated for linezolid-treated
patients. The results suggest that linezolid can be considered a
cost-effective alternative for treating patients with NP due to
suspected MRSA in France.
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OBJECTIVES: Linezolid has shown efﬁcacy in the treatment of
methicillin-resistant Staphylococcus aureus (MRSA) infections,
including nosocomial pneumonia (NP). In patients with MRSA-
NP, survival and clinical cure rate was higher for patients treated
with linezolid (80% and 59%, respectively) than those treated
with vancomycin (63.5% and 35.5%, respectively). The objec-
tive of this study is to asses the economic impact of these clinical
outcomes in the Spanish setting. METHODS: A retrospective
decision-analytical model from the hospital perspective was
applied to pooled data from 2 prospective, randomized,
controlled-double-blind studies. The model described possible
treatment outcomes for patients beginning empiric MRSA-NP
treatment. Clinical and other parameters were obtained from
published trials and from an expert panel, comprised of 5
Spanish experts experienced in treating NP. Resource use was
estimated by the expert panel. Only direct costs (€2007) were
considered. The model assumed 50% of suspected MRSA
patients had proven MRSA. Model outputs included costs/
patient, cost/death avoided, cost/life-year gained (LYG), and cost/
cure. Sensitivity analyses were carried out to test the robustness
of the model. RESULTS: The overall clinical cure rate was 11%
greater for linezolid than for vancomycin (71% versus 60%).
Average total treatment cost was €16,602 for linezolid versus
€15,823 for vancomycin-treated patients; incremental cost
€6829. Death rates were 21% (linezolid) versus 34% (vancomy-
cin), with an average 1.9 LYG per linezolid patient in a 65-year-
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old cohort (13.6 vs. 11.3 years). The incremental costs/LYG and
death avoided were €406 and €4730, respectively. Although the
model was sensitive to variables like proven MRSA percentage
and costs accrued by patients who die, varying these parameters
by 25% the overall conclusions remained the same. CONCLU-
SION: According to this model, Linezolid is cost-effective versus
vancomycin for MRSA suspected-nosocomial pneumonia in
Spain, with and additional cost/LYG and death avoided below
the acceptable threshold.
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OBJECTIVES: To assess clinical effectiveness and costs of
Augmentin ES® (amoxicillin/clavulanic acid 90/6.4 mg/kg/day in
two divided doses) vs Augmentin® conventional twice-daily
regimen (45/6.4 mg/kg/day in two divided doses) in acute otitis
media treatment in Poland from the public payer (NHF) and
payer (NHF + patient) perspective. METHODS: Systematic
review according to Cochrane Collaboration guidelines and clini-
cal effectiveness analysis according to Polish HTA Guidelines
were performed. Medline (Pubmed) Cochrane and EMBASE
were searched (August 2006). Only RCTs with high credibility
assessment (based on Jadad scale) were included in the systematic
review. Overall costs of treatment were taken into account,
including cost of pharmacotherapy, drug administration, second-
line therapy, complications of otitis media and adverse events.
Sensitivity analysis was performed according to a range of acqui-
sition costs of Augmentin ES® and Augmentin® (20%). All
calculations were performed for 2006 (€1 = PLN3.8). RESULTS:
Randomized head-to-head clinical trial of Augmentin ES® vs
conventional Augmentin® was found and signiﬁcant difference
in clinical cure rate between two drugs was revealed: 84.1% vs
78.8%, respectively; no signiﬁcant differences in safety proﬁle
were found. Cost analysis revealed that savings per patient when
Augmentin ES® is used in place of conventional Augmentin®
were: PLN28.27 (€7.4) (public payer) and PLN27.9 (€7.3)
(payer). Results of clinical and cost analysis proved that conven-
tional Augmentin® therapy is dominated by Augmentin ES®.
The results proved to be robust to variations in the drugs cost
acquired in sensitivity analysis. Savings accompanying clinical
cure of one patient in case of Augmentin ES® used in place of
Augmentin® were: PLN533.4 (€140.3) (public payer perspec-
tive) and PLN526.4) (€138.5) (payer perspective). CONCLU-
SION: Augmentin ES® compared with conventional therapy
brings signiﬁcant savings and is a cost-effective treatment of
acute otitis media in Poland.
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OBJECTIVES: To assess clinical effectiveness and costs of
Augmentin ES® (amoxicillin/clavulanic acid 90/6.4 mg/kg/day in
two divided doses) vs azithromycin (10 mg/kg, day 1; 5 mg/kg/d,
days 2–5) in acute otitis media treatment in Poland from the
public payer (NHF) and payer (NHF + patient) perspective.
METHODS: Systematic review according to Cochrane Collabo-
ration guidelines and clinical effectiveness analysis according to
Polish HTA Guidelines were performed. Medline (Pubmed)
Cochrane and EMBASE were searched (August 2006). Only
RCTs with high credibility assessment (based on Jadad scale)
were included in the systematic review. Overall costs of treatment
were taken into account, including cost of pharmacotherapy,
drug administration, second-line therapy, complications of otitis
media and adverse events. Sensitivity analysis was performed
according to a range of acquisition costs of Augmentin ES® and
azithromycin (+/-20%). All calculations were performed for
2006 (€1 = PLN3.8). RESULTS: Randomized head-to-head clini-
cal trial of Augmentin ES® vs azithromycin was found and
signiﬁcant difference in clinical cure rate between two drugs was
revealed: 90.5% vs 80.9%, respectively; no signiﬁcant differences
in safety proﬁle were found. Cost analysis revealed that savings
per patient when Augmentin ES® is used in place of azithromy-
cin were: PLN49 (€12.9) (public payer) and PLN38.3 PLN
(€10.1) (payer). Results of clinical and cost analysis proved that
azithromycin therapy is dominated by Augmentin ES®. The
results proved to be robust to variations in the drugs cost
acquired in sensitivity analysis. Savings accompanying clinical
cure of one patient in case of Augmentin ES® used in place of
azithromycin were: PLN510.5 (€134.3) (from public payer per-
spective) and PLN399.2 (€105) (payer perspective). CONCLU-
SION: Augmentin ES® compared with azithromyycin therapy
brings signiﬁcant savings and is a cost-effective treatment of
acute otitis media in Poland.
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OBJECTIVES: HPV epidemiology and screening practices vary
considerably between countries and speciﬁc analyses are required
to estimate the impact of prophylactic cervical cancer vaccination.
This study adapted a health economic model to Italy to predict the
clinical and economic impact. METHODS: A Markov model
based upon the natural history of HPV and cervical cancer was
developed to simulate transitions between health states (normal,
HPV, Cervical Intraepithelial Neoplasia stages 1 to 3, Cervical
Cancer (CC) stages 1 to 4, and death) in the presence of speciﬁc
screening programs. Italian data was used to for costs, and
screening and treatment practices, and published clinical data was
used to estimate efﬁcacy against oncogenic HPV types 16, 18, 31,
45. The model was calibrated to Italian epidemiological data
including age-speciﬁc HPV prevalence, prevalence of CIN lesions,
CC incidence and mortality. The cost-effectiveness of vaccination
against HPV for cohorts of different ages was assessed using the
calibrated model. RESULTS: With 100% vaccine coverage, in a
12 year old cohort of females there is estimated to be a 68%
reduction in the prevalence of high-grade precancerous lesions due
to oncogenic HPV, and a 78% and 79% reduction in cervical
cancer cases and deaths, respectively. Vaccination would also
produce substantial reductions in these outcomes for the 18 and
25 year old cohorts, and in the number of screening tests and
treatments required. With 3% discount rates on costs and out-
comes, vaccination is cost effective in cohorts of 12, 18, and 25
year oldswith estimated cost perQALYs of €30,624, €31,078, and
€31,116 respectively. CONCLUSION: The model was success-
fully adapted to represent Italian epidemiological data, screening
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